1World Health Organization. The World Health report 1996: fighting dis-ease, fostering development [J].Report of the Director -General.Geneva:World Health Organization, 1996.
2Guerrant RL. Why America must care about tropical medicine: threats toglobal health and security from tropical infectious diseases [J].Am J TropMed Hyg, 1998(59):3-16.
3Wang XY, Du L, Von Seidlein L, et al.Occurrence of shigellosis in theyoung and elderly in rural China: results of a 12 -month population -based surveillance study[J].Am J Trop Med Hyg, 2005 ( 73 ) :416-422.
4Herikstadt H, Vergia D,Hadler J, et aL Population-based estimate of the bur-den of diarrheal illnesses: FoodNet 1996-1997 [J].lst International Confer-ence on Emerging Infectious Diseases (Atlanta), March 1998.
5National Institute of Allergy and Infectious Diseases (NIAID). Foodbomedisease fact sheet. 1999. Available at: http://www.niaid.nih.gov/ fact-sheets/foodbomedis.htm. Accessed 23 January 2001.
8Qu F, Bao C, Chen S, et al . Genotypes and antimicrobial profiles ofShigella sonnei isolates from diarrheal patients circulating in Beijing be-tween 2002 and 2007[J].Diagn Microbiol Infect Dis, 2012,74(2): 166-170.
10Taneja N, Mewara A,Kumar A, et al. Cephalosporin-resistant Shigellaflexneri over 9 years (2001-09) in India [J].J Antimicrob Chemothe,2012,67(6):1347-1353.
二级参考文献23
1Kotloff KL, Noriega FR, Samandari T, et al. Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect Immun, 2000,68: 1034-1039.
2Kotloff KL, Nataro JP, Losonsky GA, et al. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine, 1995,13 : 1488-1494.
3Noriega FR, Liao FM, Maneval DR, et al. Strategy for cross-protection among Shigella flexneri serotypes. Infect Immun, 1999, 67:782-788.
4Chompook P, Todd J, Wheeler JG, et al. Risk factors for shigellosis in Thailand. Int J Infect Dis,2006,10:425-433.
5Kotloff KL, Winickoff JP, Ivanoff B, et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ, 1999,77 : 651-666.
6von Seidlein L, Kim DR, Ali M, et al. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Med, 2006, 3 : e353.
7Sivapalasingam S, Nelson JM, Joyee K, et al. High prevalence of antimicrobial resistance among Shigella isolates in the United States tested by the National Antimicrobial Resistance Monitoring System from 1999 to 2002. Antimicrob Agents Chemother, 2006,50:49- 54.
8Ozmert EN, Gokturk B, Yurdakok K, et al. Shigella antibiotic resistance in central Turkey: comparison of the years 1987-1994 and 1995-2002. J Pediatr Gastroenterol Nutr, 2005, 40:359-362.
9Dutta S, Rajendran K, Roy S, et al. Shifting serotypes, plasmid profile analysis and antimicrobial resistance pattern of shigellae strains isolated from Kolkata, India during 1995 -2000. Epidemiol Infect, 2002,129:235-243.
10Fulla N, Prado V, Duran C, et al. Surveillance for antimicrobial resistance profiles among Shigella species isolated from a semirural community in the northern administrative area of Santiago, Chile. Am J Trop Med Hyg, 2005,72:851-854.
